News

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, MD, a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Ovarian cancer screening for women who do not have symptoms of the disease may do more harm than good, according to the USPSTF.

How patients can be their own advocates and maximize their care team appointments by speaking up and asking questions.

Currently, myleproliferative neopasms are not on the Vereran's Health Administration presumptive list but MPN Advocacy and Education International is working to change that.

Karley Trautman, DNP, ANP-BC, explains her efforts to improve the rates of venous thromboembolism (VTE), as well as the rates of recurrence of VTE in the Blood Cancer and Bone Marrow Transplant program of University of Colorado Hospital.

The immunotherapy agent, avelumab (Bavencio) is the first drug to receive approval to treat Merkel cell carcinoma (MCC), a rare form of skin cancer. Carrie Best was the first patient to enroll in a clinical trial of avelumab, the first to receive the drug for Merkel cell carcinoma, and the first to become cancer-free.

Expert Jeffrey Lancet, MD, discusses the emerging agents in treating acute myeloid leukemia (AML) and challenges that still exist for improving patient outcome.

Hair repigmentation in patients receiving anti-PD-1/anti-PD-L1 treatment may be a response marker.

The FDA has approved neratinib (Nerlync) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Observing the Warburg effect, researchers found that properties of the ketogenic diet could have a positive effect on outcomes for patients with glioma.

Moving Forward Together 3 is a study evaluating how to get breast cancer survivors exercising, by using other breast cancer survivors as coaches.

A recent study found that those who survived the Holocaust had an increased rate of lung and colorectal cancer.

Nivolumab (Opdivo) improved quality of life scores in most patients with head and neck squamous cell carcinoma (HNSCC).

The treatment landscape of ovarian cancer continues to change with the recent approvals of new agents.

According to new research, pregnancy does not increase the risk of recurrence for women who have had early breast cancer.

For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.

Patients with lung cancer who received low-dose CT scans had a 15% to 20% lower risk of death from their disease versus those who had standard chest X-rays, which has led to screening guidelines.

Barriers to clinical trials can more acutely affect patients in minority and other groups -- such as the elderly.

Maintenance rucaparib may improves progression-free survival in patients with ovarian cancer.

Clinicals can use mutiple-gene panels to identify mutations to test for breast cancer and ovarian cancer risk.

The Visible Ink program at Memorial Sloan Kettering Cancer Center helps patients and survivors express their stories and feelings through writing.

Inaccurate ideas of palliative care can negative effect the outcomes for patients with lung cancer.

The occurence of hand-foot skin response could signal regorafenib activity in hepatocellular cancer.

For patients with high-risk melanoma, the best option is effective adjuvant therapy which necessitates clincal trials.

The risk of developing certain types of cancer can be increased by exposure to work-related stress.

The FDA accepted supplemental biologics license application (sBLA) for the use of denosumab (Xgeva) for the prevention of skeletal-related events (SREs) in patients with multiple myeloma.

The indication for the DigniCap Cooling System has been expanded by the FDA to include alopecia reduction across all solid tumors.

The US Preventive Services Task Force (USPSTF) does not agree with the need for yearly full-body skin exams, which many healthcare providers support.